Stéphanie Guéret

Director & Team Leader Medicinal Chemistry | Early CVRM | BioPharmaceuticals R&D | AstraZeneca

Greater Gothenburg Metropolitan Area

About

Experience

  • AstraZeneca (Full-time · 11 yrs 5 mos)
    • Director Medicinal Chemistry
      Aug 2025 - Present · 11 mos

      - Team leader of experienced synthetic and medicinal chemists - Lead medicinal chemist for projects in LO and pre-clinical phases

    • Associate Principal Scientist, Medicinal Chemistry
      Apr 2021 - Sep 2025 · 4 yrs 6 mos

      - Winner of AZ RnD awards for project acceleration with successful phase transition and Winner of the patent of the year. - Project Leader for metabolism program from Lead Generation to Lead Optimization. - Chemistry Leader of small molecule project with successful candidate investment decision in record timeline compared to company average. - Chemistry Leader of metabolism small molecule project from Hit Discovery to Lead Optimization with successful transition phases achieved.

    • Senior Research Scientist, Medicinal Chemistry
      Sep 2019 - Mar 2021 · 1 yr 7 mos

      - Synthesis and design of small molecules as well as external chemists coordinator during Lead Generation and Lead Optimization phases. - Co-inventor of small molecule which achieved candidate selection for CVRM application.

  • Presidential Postdoctoral Research Fellow at NIBR at Novartis
    Dec 2011 - Jan 2015 · 3 yrs 2 mos

    - Discovered and established an efficient cyclization method to access a new class of cyclic peptidomimetics. - Interacted with biologists and interdisciplinary research teams involved in pharmaceutical development to study the biological relevance of the new motif in the opioid receptors. - Studied and improved the pharmacokinetic and ADME properties of the obtained cyclic pseudopeptides. - Participated in the design of a new chemical library and in the protein-protein interactions (PPI) working group. - Organized postdoc lunch seminar series and events related to the Novartis Basel postdoc community.

  • Postdoctoral Research Fellow in Medicinal Chemistry at The University of Auckland
    Apr 2011 - Sep 2011 · 6 mos

    Design and synthesis of TrpD transition state analogues as novel anti-tuberculosis drugs in the research group of Prof. Brimble under the New Economy Research Fund (NERF) grant project and in close collaboration with Prof. Edward N. Baker and Dr. Shaun Lott, School of Biological Sciences, University of Auckland (New Zealand)

  • Research Scientist at AgResearch
    Oct 2010 - Mar 2011 · 6 mos

    Synthesis of substituted carbazoles as novel anthelmintic agents in the laboratory of organic and medicinal chemistry of Prof. Brimble for ParaCo Technology Ltd., a wholly-owned subsidiary of AgResearch Ltd. (New Zealand)

  • PhD Research at The University of Auckland
    Nov 2006 - Dec 2010 · 4 yrs 2 mos

    Total synthesis of natural products "Synthetic studies towards the spiroimine unit of the spirolides" under the supervision of Prof. Margaret A. Brimble. - Synthesized complex enantiopure spirolactams and spiroimines using as key steps: hydrogenation, selective formation of stereocenters, diastereoselective Birch reductive alkylation and Diels-Alder reactions. - Developed novel retrosynthesis pathways and alternative methodologies to obtain the final desired natural product (enantiopure 7,6-spiroketimine unit of the Spirolides). - Managed laboratory functions including organization, chemical stock and troubleshooting of technical problems. - Supervision of Master students and new PhD candidates. 2010 – Contractor for AFT Pharmaceuticals - large scale (50 g) synthesis of a antirheumatic drug in purity above 99%. 2007 to 2010 – Teaching experience of undergraduate students in the laboratory and marking of laboratory reports and exams. Limited Term Tutor (chemistry and medicinal chemistry) for first, second and third years.